AstraZeneca PLC AstraZeneca to transfer rights to Eklira, Duaklir (8147Q)
01 November 2021 - 6:00PM
UK Regulatory
TIDMAZN
RNS Number : 8147Q
AstraZeneca PLC
01 November 2021
1 November 2021 07:00 GMT
AstraZeneca to transfer global rights for Eklira and Duaklir to
Covis Pharma
Agreement sharpens AstraZeneca's focus on priority medicines
in Respiratory & Immunology portfolio
AstraZeneca has agreed to transfer its global rights to Eklira
(aclidinium bromide), known as Tudorza in the US, and Duaklir
(aclidinium bromide/formoterol) to Covis Pharma Group (Covis
Pharma).
Both medicines are delivered via the Genuair device and used for
the treatment of patients with chronic obstructive pulmonary
disease (COPD).
The agreement will ensure continued patient access to these
established medicines.
Covis Pharma previously acquired the rights to the respiratory
medicines Alvesco, Omnaris and Zetonna from AstraZeneca in
2018.
Financial considerations
Covis Pharma will pay AstraZeneca $270m on completion. Covis
Pharma will also cover certain ongoing development costs related to
the medicines. The income arising from the upfront payment will be
fully offset by a charge for derecognition of the associated
intangible asset and therefore no Other Operating Income will be
recognised in AstraZeneca's financial statements. In 2020, Eklira
and Duaklir generated AstraZeneca revenue of $143m in the countries
covered by this agreement.
The transaction is expected to close in the fourth quarter of
2021, subject to customary closing conditions and regulatory
clearances. The agreement will not impact the Company's financial
guidance for 2021.
Eklira and Duaklir
Eklira (aclidinium bromide) and Duaklir (aclidinium
bromide/formoterol) are inhaled respiratory medicines used for the
maintenance treatment of COPD. Eklira is a long-acting muscarinic
antagonist (LAMA), which is marketed in the US as Tudorza and in
some countries as Bretaris. Duaklir is a combination therapy that
contains both a LAMA and a long-acting beta2-agonist (LABA). It is
marketed in some countries as Brimica. Both medicines are presented
as a dry powder for inhalation and are delivered via a
breath-actuated multi-dose dry powder inhaler, Genuair (Pressair in
the US). AstraZeneca licensed the global rights to both products
from Almirall S.A. in 2014.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team,
please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFERIALLVIL
(END) Dow Jones Newswires
November 01, 2021 03:00 ET (07:00 GMT)
Astrazeneca (LSE:0A4J)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:0A4J)
Historical Stock Chart
From Apr 2023 to Apr 2024